Biogen (BIIB) EBT Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Biogen (BIIB) EBT Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -801,907.00 |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 29,565.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,328.00 |
| Mar 31, 2026 | 244.00 |
| Dec 31, 2025 | -1,433.00 |
| Sep 30, 2025 | 370.00 |
| Jun 30, 2025 | -22.00 |
| Mar 31, 2025 | -749.00 |
| Dec 31, 2024 | -34.00 |
| Sep 30, 2024 | 2,387.00 |
| Jun 30, 2024 | -49.00 |
| Mar 31, 2024 | 250.00 |
| Dec 31, 2023 | -1,151.00 |
| Sep 30, 2023 | -6,024.00 |
| Jun 30, 2023 | -2,020.00 |
| Mar 31, 2023 | 407.00 |
| Dec 31, 2022 | 892.00 |
| Sep 30, 2022 | 4,418.00 |
| Jun 30, 2022 | 2,806.00 |
| Mar 31, 2022 | -361.00 |
| Dec 31, 2021 | 244.00 |
| Sep 30, 2021 | -1,789.00 |